Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Current Leases (2023 - 2025)

Ascentage Pharma Group International posted quarterly Current Leases of $1.0 million for Q4 2025, down 21.86% year-on-year from $1.3 million in Q4 2024, and down 21.86% on a QoQ basis from $1.3 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 3 years of Current Leases data on file, last reported at $1.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 21.86% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (down 21.86% YoY), and the FY2025 full-year result was $1.0 million, down 19.49% from the prior year.
  • Current Leases for Q4 2025 stood at $1.0 million, down from $1.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.4 million in Q4 2023 and bottomed at $1.0 million in Q4 2025.
  • The 3-year median for Current Leases is $1.3 million (2024), against an average of $1.2 million.
  • The widest annual swing landed in 2024, when Current Leases declined 3.03%; it then slipped 21.86% in 2025.
  • A 3-year view of Current Leases shows it stood at $1.4 million in 2023, then dropped by 3.03% to $1.3 million in 2024, then retreated by 21.86% to $1.0 million in 2025.
  • The last three Current Leases figures came in at $1.0 million (Q4 2025), $1.3 million (Q4 2024), and $1.4 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 83,991.00
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 7.40 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 720.00 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 45.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 1.03 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.03 Mn
Dec 31, 2024 1.31 Mn
Dec 31, 2023 1.36 Mn